Emmanuel Kiyonga is a pharmaceutical researcher and master’s student at Sefako Makgatho Health Sciences University (SMU) in South Africa. He has developed a novel drug, Raloxifene Hydrochloride Hydrate Solvate, aimed at improving the treatment of postmenopausal osteoporosis and breast cancer. This innovation enhances the solubility and efficacy of existing treatments, potentially benefiting millions of patients worldwide.
In recognition of his groundbreaking work, Kiyonga was awarded R100,000 and named Studentpreneur of 2024 at the EDHE Entrepreneurship Intervarsity 2024 competition. His invention also led to SMU registering its first-ever patent, marking a significant milestone for the institution.
Kiyonga’s journey is marked by resilience and dedication. Originally from Kampala, Uganda, he overcame financial hardships and educational challenges before moving to South Africa in 2009. At SMU, he pursued studies in Occupational and Environmental Health, later transitioning to Pharmacy, where he made his notable discovery.
His achievements have garnered widespread attention, including features on platforms like OkayAfrica. Additionally, Kiyonga has contributed to academic literature, co-authoring publications on pharmaceutical innovations.
